Novo Nordisk A/S (NVO) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 27/100
- 10Y CAGR
- 11.9%
- Median YoY
- 9.6%
- YoY volatility
- σ 11.8pp· uneven
- Quarters ≥ 20%
- 10 of 40
- Negative quarters
- 6
- Valuation vs own 10Y history
- P/S 4.0x · 10Y median 7.8x · 4th percentile · as of Aug 19, 2026
How this score is computed
- Quarters at or above 20%: 10 of 40 → 10 of 40 pts
- Steadiness (typical swing 11.8pp) → 16.6 of 25 pts
- Pace (median 9.6% YoY) → 0 of 20 pts
- Latest quarter (-1.2% YoY) → 0 of 15 pts
- Score: 27 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 11.9% | 9.6% | 11.8pp | 10 of 40 | 6 |
| EPSEPS | 13.9% | 11.1% | 22.3pp | 11 of 40 | 6 |
| Op cash flowOperating cash flow | 12.9% | 13% | 38.4pp | 16 of 39 | 15 |
| EBITDAEBITDA | 11.9% | 9.7% | 16.6pp | 11 of 40 | 5 |
| FCFFree cash flow | -0.2% | 12% | 43.2pp | 12 of 35 | 13 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: NVO on the compounders surface · All compounders, ranked